Skin

Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development

Retrieved on: 
Thursday, March 14, 2024
Research, Database, Gene expression, Disease, Patient, Accounting, OLE, Insurance, Ataxia, Clinical trial, Skin, Therapy, Safety, Pharmacokinetics, Interim, FA, FDA, BLA, Pharmaceutical industry

BALA CYNWYD, Pa., March 14, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its fourth quarter and full year 2023 operating and financial results.

Key Points: 
  • BALA CYNWYD, Pa., March 14, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its fourth quarter and full year 2023 operating and financial results.
  • Nomlabofusp was generally well-tolerated and demonstrated dose-dependent increases in skin and buccal cell frataxin levels.
  • Research and development expenses for the fourth quarter of 2023 were $10.6 million compared to $7.2 million for the fourth quarter of 2022.
  • General and administrative expenses for the fourth quarter of 2023 were $3.5 million compared to $3.2 million for the fourth quarter of 2022.

Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases

Retrieved on: 
Wednesday, March 13, 2024
COL7, FAP, Cancer, Patient, APC, Mouse, ALM, Ribosome, BME, Gastrointestinal disease, OTC, Skin, Polyp (medicine), Therapy, Kidney, Pharmaceutical industry

BARCELONA, Spain and WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC: ELOX) announced today that the companies have entered into an exclusive license agreement for the asset ZKN-013.

Key Points: 
  • BARCELONA, Spain and WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC: ELOX) announced today that the companies have entered into an exclusive license agreement for the asset ZKN-013.
  • Under the agreement, Almirall obtains global rights to develop and commercialize ZKN-013, including for the use in orphan dermatological diseases.
  • ZKN-013 is a potentially promising oral, nonsense mutation readthrough drug, which enables the host cells to produce functional proteins which counteract the root cause of these rare dermatological and potentially other diseases.
  • The drug candidate is expected to shortly enter into Phase I development in healthy volunteers.

Soft Glow SPF 50+ Wins Best in Finished Formula-Prestige Category at 2024 Cosmetics & Toiletries Allē Awards

Retrieved on: 
Wednesday, March 13, 2024
Radiation, UV, Antioxidant, SPF, C&T, Tocopherol, Common sunflower, Skin, Creativity, Cosmetics, Allured Business Media, Magic

This win marks the second Allē Award that Solésence Beauty Science has received.

Key Points: 
  • This win marks the second Allē Award that Solésence Beauty Science has received.
  • In 2022, their Solésence Kleair™ technology won the Cosmetics & Toiletries Allē Awards in the Sun/Light Protection category.
  • Soft Glow SPF 50+ is a featherweight serum that contains non-nano, mineral-based, broad-spectrum SPF 50+ sunscreen that protects the skin from 98%+ of UV radiation and reduces pollution-induced free radicals by over 85% while protecting against blue light (HEVL).
  • More information about Solésence, their proprietary technologies, paths to market, and product offerings, can be found on their website .

Current shareholder and former institutional portfolio manager, Nilesh Undavia, issues an open letter to GrafTech International Ltd. Shareholders

Retrieved on: 
Tuesday, March 12, 2024
Carbon, ACT, TSR, CFO, ALL, Tokai Carbon, IPO, HIS, Adjustment, UNIT, GrafTech, Skin, Proxy, DIRECT, WHO, ABLE, USD, Management

Since 2019 (the first full year after the IPO), GrafTech’s Revenue has declined by 65% and Adjusted EBITDA has collapsed by 98%.

Key Points: 
  • Since 2019 (the first full year after the IPO), GrafTech’s Revenue has declined by 65% and Adjusted EBITDA has collapsed by 98%.
  • Yet, the Board and management appear to have no credible strategy or plan to address the underlying failures of the core business.
  • Currently, the board has only one director out of seven total members1, with outside experience in the steel industry that GrafTech serves.
  • All of the remaining board members appear to lack relevant and transferrable expertise specific to GrafTech.

Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge

Retrieved on: 
Tuesday, March 12, 2024
Dermatology, Atopic dermatitis, Inflammation, JNJ, Research, American Academy, Cancer, FABP5, Skin, FABP, Pain, Epidermis, Oxidative stress, Pharmaceutical industry

SOLANA BEACH, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced its selection as a finalist in Johnson & Johnson’s (“J&J’s”; NYSE: JNJ) Innovation Challenge .

Key Points: 
  • SOLANA BEACH, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced its selection as a finalist in Johnson & Johnson’s (“J&J’s”; NYSE: JNJ) Innovation Challenge .
  • Artelo was awarded the opportunity to present preclinical dermatology research on ART26.12 in San Diego, California, on March 11, 2024, concurrent with the American Academy of Dermatology Annual Meeting.
  • "We are pleased to have been selected to present our ART26.12 program to the J&J immuno-dermatology leadership team," said Dr. Andrew Yates, Chief Scientific Officer of Artelo.
  • “Our drug discovery program is investigating several oral, small molecule, FABP5 inhibitors,” said Professor Saoirse O'Sullivan, Vice President Translational Science of Artelo.

Procter & Gamble Recalls 8.2 Million Defective Bags of Tide, Gain, Ace and Ariel Laundry Detergent Packets Distributed in US Due to Risk of Serious Injury

Retrieved on: 
Friday, April 5, 2024
Discount, Variety, Parenting, Children, Supermarket, Home Goods, Family, Consumer, Retail, Online Retail, Risk, Eye, Tide Pods, Multimedia, Death, Procter & Gamble, Child, Skin, Medical device

Procter & Gamble (NYSE:PG) today announced a voluntary packaging recall of Tide Pods, Gain Flings, Ace Pods and Ariel Pods liquid laundry detergent packets packaged in flexible film bags.

Key Points: 
  • Procter & Gamble (NYSE:PG) today announced a voluntary packaging recall of Tide Pods, Gain Flings, Ace Pods and Ariel Pods liquid laundry detergent packets packaged in flexible film bags.
  • This recall announcement applies only to bags distributed in the United States.
  • Consumers with recalled bags can submit a photo of the recalled product, showing the lot code, to participate in the recall.
  • Recalled products range from bags with 12 to 39 laundry detergent packets and include the following:

Korea Cosmetics (K-Beauty) Market Analysis Report 2024-2029: Brands are Losing Out in the Chinese Market to Local Players in the Mass Segment and to Global Players in the Premium Segment - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 4, 2024
Cosmetics, Retail, Delivery Services, Olive, Skin care, Growth, Olive Young, Beauty, COVID-19, Internet, Research, ODM, Female, DIY, Sale, Social media, Woman, City, Supermarket, OEM, Skin, Traction, Market, Government, Production

The Korea cosmetics market value stood at US$6.57 billion in 2023, and is expected to reach US$9.05 billion by 2029.

Key Points: 
  • The Korea cosmetics market value stood at US$6.57 billion in 2023, and is expected to reach US$9.05 billion by 2029.
  • Geographically, the market is not limited to a specific region within Korea but has a significant presence throughout the country.
  • Korean brands are losing out in the Chinese market to local brands in the mass segment and to global players in the premium segment, leading to inevitable and painful restructuring.
  • The report provides the bifurcation of the Korea cosmetics market into two segments based on category, premium products and mass products.

Corti Set to Disrupt the Health Wearable Market with the First Real-time, Continuous Monitor for Cortisol and Melatonin Hormones, the Key Stress and Sleep Hormones

Retrieved on: 
Thursday, April 4, 2024
Wearables, Mobile Technology, Technology, Mental Health, Fitness & Nutrition, Health Technology, Other Health, Health, General Health, Consumer Electronics, Moses Austin, Benchmarking, Hormone, Exercise, Professor, Inflammation, Biomarker, Research, Sleep, Melatonin, University, Doctor of Philosophy, Life, Eye, Diet, Management, Publication, Skin, Cortisol, Ageing, Medical device

The wearable features its proprietary passive-sweat sensor technology that non-invasively rests on your skin, day and night, continuously measuring biomarker levels.

Key Points: 
  • The wearable features its proprietary passive-sweat sensor technology that non-invasively rests on your skin, day and night, continuously measuring biomarker levels.
  • Now, it provides users with unmatched real-time insights into their wellness, establishing a new benchmark for the continuous monitoring of these critical biomarkers.
  • Corti redefines health monitoring by offering continuous, real-time visibility into the body's key stress and sleep hormones, Cortisol and Melatonin, marking a first in the wearable market.
  • Moreover, we are actively working with partnering businesses to discover new applications, enhancing its integration into various health and wellness ecosystems.

Biolinq Raises $58 Million to Advance Wearable Biosensors Through Pivotal Trial for Metabolic Health Using Precision Microsensor Technology

Retrieved on: 
Thursday, April 4, 2024
Research, Other Health, Pharmaceutical, Technology, Medical Devices, Clinical Trials, Science, Nanotechnology, Biotechnology, Wearables, Mobile Technology, Health, Diabetes, Other Science, Aphelion, AXA, Taisho Pharmaceutical, Skin, Bleeding, Needle, Multimedia, FDA, Incorporated, Silicon

J.P. Morgan served as placement agent to Biolinq in connection with the financing.

Key Points: 
  • J.P. Morgan served as placement agent to Biolinq in connection with the financing.
  • “Our technology approach enables access to a coveted, metabolically active compartment of the skin for biosensing without the use of introducer needles or bleeding,” said Rich Yang, CEO, Biolinq.
  • “Companies that disrupt entire industries often don’t originate from a single discipline,” said Rick Gerson, Chairman of Alpha Wave Global.
  • “Biolinq has attracted leading experts in biosensor development, consumer electronics design, proprietary materials science, software engineering and semiconductor manufacturing to build a new category of biowearables.

Trex and REI Co-op Team Up to Expand Signature Camping Experience near Bryce Canyon National Park

Retrieved on: 
Wednesday, April 3, 2024
Banking, Architecture, Professional Services, Consumer, Residential Building & Real Estate, Commercial Building & Real Estate, Other Manufacturing, Construction & Property, Other Consumer, Building Systems, Landscape, Finance, Manufacturing, Recycling, ESG, Polyethylene, Travel, Light, Wood, TREX, Skin, Water, REI, Multimedia, Collection, Marketing, Snow

When it came time for REI to expand its Signature Camp near Bryce Canyon National Park in Utah, it was only natural that the brands work together to highlight the full-circle efforts at REI’s private campsite.

Key Points: 
  • When it came time for REI to expand its Signature Camp near Bryce Canyon National Park in Utah, it was only natural that the brands work together to highlight the full-circle efforts at REI’s private campsite.
  • Nature lovers can now enjoy the great outdoors from tent set-ups situated on elevated platforms made from Trex composite decking.
  • Bringing these efforts full circle to REI’s campsite, the company worked with Trex to build 10 elevated decking platforms at its Signature Camp near Bryce Canyon.
  • Another reason REI chose Trex decking for its Bryce Canyon campsite is practicality.